FDA label 83605e7c-39bf-9666-c6fd-23b5eeb14b5d

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
6720fab5-6ef0-e922-0c2c-2fe5280838ab
SPL ID
83605e7c-39bf-9666-c6fd-23b5eeb14b5d
Version
4
Effective date
2012-12-12
Source export date
2026-09-28
Source partition
1
Source file
https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-09-28/9c7783846d422acb0c9e59457606951c785a7d28cc631c8cc4839d0dc7c55f39/drug-label-0001-of-0014.json.zip
Source manifest SHA-256
cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run
20260929T050834Z
Imported at
2026-09-29 05:13:26

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 2 matching rows.

warnings

WARNINGS: Choking Hazard; small parts. Keep out of reach of children.

warnings and cautions

PRECAUTIONS: Topical application of AHEALON may cause initial stinging, with progressive desensitization as treatment progresses. Carefully adjust AHEALON dosage to those who might be hypersensitive to any of the ingredients of this drug. Hypersensitivity: Caution should be used when administering to patients with a history of contact sensitivity to sulfur or silver or to the other ingredients that comprise this drug. Information for patients: Patients using AHEALON should receive the following information and instructions: AHEALON is to be used throughout the healing process only as directed by your physician. It is important to systematically follow physician advised application times; do not skip AHEALON applications and/or double applications. Drug Interactions: There are no known AHEALON drug interactions. Carcinogenesis, mutagenesis, and impairment of fertility: No studies have been done on the carcinogenesis, mutagenesis, or impairment of fertility of AHEALON. In general, at the dilutions herein formulated, homeopathic drugs are not known to cause direct or indirect harm to a fetus. AHEALON should be given to a pregnant woman only if clearly needed. Effects of each ingredient is not listed as a carcinogen by ACGIH, IARC, NIOSH, NTP, or OSHA; each is a GRAS substance: generally recognized as safe. Pregnancy Category C. Animal reproduction studies have not been conducted with AHEALON. Pregnant women are given AHEALON only if clearly needed. Nursing mothers: It is not known whether this drug is secreted in human milk. However, since many drugs are secreted in human milk, caution should be exercised when AHEALON is administered to a nursing woman. Pediatric use: Carefully adjust AHEALON dosage when treating young children who might have a hypersensitivity to any of the ingredients of this drug.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS: AHEALON contains low doses of active ingredients. Therefore there are minimal known side effects. (see PRECAUTIONS for hypersensitivity information)

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.